Cytokinetics, Incorporated
CYTK
Rank in Stocks
#2296
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Share Price
$62.83
Market Cap
$8.73B
Change (1 day)
-1.75%
Change (1 year)
8.74%
Country
US
Trade Cytokinetics, Incorporated (CYTK)
Category
Healthcare
Stock price history for Cytokinetics, Incorporated (CYTK)
Highest end of day price: $62.96 on 2026-10-01
Lowest end of day price: $97.08 on 2004-04-01
Lowest end of day price: $97.08 on 2004-04-01
Stock price history of Cytokinetics, Incorporated from 2004 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 8.63% |
| 2025 | 28.55% |
| 2024 | 11.95% |
| 2023 | 4.76% |
| 2022 | 4.97% |
| 2021 | 101.81% |
| 2020 | 97.15% |
| 2019 | 42.08% |
| 2018 | -14.22% |
| 2017 | -29.65% |
| 2016 | 4.66% |
| 2015 | 114.65% |
| 2014 | -19.66% |
| 2013 | 59.81% |
| 2012 | -32.39% |
| 2011 | -55.97% |
| 2010 | -23.56% |
| 2009 | 26.62% |
| 2008 | -55.25% |
| 2007 | -26.58% |
| 2006 | -3.72% |
| 2005 | -20.38% |
| 2004 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
